Methylphenidate

( DrugBank: Methylphenidate / KEGG DRUG: Methylphenidate hydrochloride, Methylphenidate )


5 diseases
IDDisease name (Link within this page)Number of trials
6Parkinson disease8
13Multiple sclerosis5
34Neurofibromatosis1
IDDisease name (Link within this page)Number of trials
84Sarcoidosis3
113Muscular dystrophy1

6. Parkinson disease


Clinical trials : 2,586Drugs : 1,871 - (DrugBank : 354) / Drug target genes : 188 - Drug target pathways : 205 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

13. Multiple sclerosis


Clinical trials : 3,685Drugs : 1,932 - (DrugBank : 355) / Drug target genes : 263 - Drug target pathways : 237 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

34. Neurofibromatosis


Clinical trials : 165Drugs : 189 - (DrugBank : 83) / Drug target genes : 93 - Drug target pathways : 209 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

84. Sarcoidosis


Clinical trials : 175Drugs : 189 - (DrugBank : 80) / Drug target genes : 74 - Drug target pathways : 177 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

113. Muscular dystrophy


Clinical trials : 766Drugs : 477 - (DrugBank : 119) / Drug target genes : 80 - Drug target pathways : 178 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries